<DOC>
	<DOCNO>NCT01539226</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled study ass safety efficacy silicone elastomer vaginal matrix ring .</brief_summary>
	<brief_title>Safety Efficacy Trial Dapivirine Vaginal Matrix Ring Healthy HIV-Negative Women</brief_title>
	<detailed_description>A multi center , randomize , double-blind , placebo=controlled safety efficacy trial Dapivirine Vaginal Matrix Ring healthy HIV-negative woman .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women &gt; 18 &lt; 45 year age , screening , provide informed consent ; Available visit consent follow procedure schedule trial ; Selfreported sexually active ( defined average least one penetrative penilevaginal coital act per month last 3 month prior screen ) ; HIVnegative determine HIV algorithm apply screen enrolment ; On stable form contraception define within section 5.4 willing continue stable contraception duration clinical trial , unless postmenopausal surgically sterilise ; Asymptomatic genital infection time enrolment ( woman diagnose clinically significant curable STI , must initiate treatment least 1 week prior enrolment complete full course treatment ) ; Willing provide adequate locator information trial retention purpose reachable per local standard procedure ( e.g. , home visit telephone ; via family close neighbour contact ) ; confidentiality maintain ; Willing refrain participation another research trial use drug , vaccine , medical device , microbicides oral preexposure prophylaxis investigational drug duration IPM 027 trial . Currently pregnant last pregnancy within 3 month prior screen intend become pregnant trial participation ; Currently breastfeed ; Nontherapeutic injection drug use 12 month prior screen ; Participated another research trial use drug , medical device , microbicides oral preexposure prophylaxis agent within 60 day prior screen ; Previously participate currently participate HIV vaccine trial ; Untreated , clinically significant urogenital infection , e.g. , urinary tract , sexually transmitted infection , gynaecological symptom within 1 week prior enrolment ; Has Grade 2 high pelvic examination finding , accord Division AIDS Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies ; History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , diagnose chronic and/or recurrent vulvovaginal candidiasis , urethral obstruction , incontinence urge incontinence ; Any gynaecological surgery within 90 day prior screen ; Any Grade 1 high baseline aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , platelet count , Grade 2 high baseline haematology , chemistry urinalysis laboratory value accord Division AIDS Table Grading Severity Adult Pediatric Adverse Events ; Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone elastomer ; Any history diabetes mellitus chronic use oral corticosteroid therapy ; uncontrolled serious chronic progressive disease ; Cervical cytology screen require cryotherapy , biopsy treatment ( infection ) . Women Grade 1 cervical cytology finding enrol upon completion initial phase evaluation current treatment indicate ( base local standard care management abnormal cervical cytology ) ; Any condition ( ) , opinion investigator , might put participant risk , interfere trial objective participant 's adherence trial requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>